Clinical trial · Observational
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
NCT04022616CI-TRIAL-00107400recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Specimen collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Immediate Surgery
- description
- Adult patients with breast malignancy.
- interventionNames
- Other: Specimen collection
- label
- Neo-adjuvant Chemotherapy
- description
- Adult patients with biopsy proven operable breast cancer who in the opinion of treating physician are suited to receive neo-adjuvant chemotherapy.
- interventionNames
- Other: Specimen collection
- label
- Lymph Node Tissue
- description
- Adult patients with breast malignancy who will be having a primary lymph node removed during breast surgery.
- interventionNames
- Other: Specimen collection
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older * Ability to give informed consent * Stage I-III breast malignancy Exclusion Criteria: * Unable to tolerate venipuncture
References
Publications (1)
- DERIVEDWesolowski R, Stiff A, Quiroga D, McQuinn C, Li Z, Nitta H, Savardekar H, Benner B, Ramaswamy B, Lustberg M, Layman RM, Macrae E, Kassem M, Williams N, Sardesai S, VanDeusen J, Stover D, Cherian M, Mace TA, Yu L, Duggan M, Carson WE 3rd. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer. BMC Cancer. 2020 May 19;20(1):445. doi: 10.1186/s12885-020-06949-4. PMID 32429929